Free Trial
Notice: Trading of InMed Pharmaceuticals halted at 09:47 AM EST due to "LULD pause".
NASDAQ:INM

InMed Pharmaceuticals (INM) Stock Price, News & Analysis

InMed Pharmaceuticals logo
$5.05 +0.10 (+2.02%)
Closing price 04:00 PM Eastern
Extended Trading
$4.18 -0.87 (-17.19%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About InMed Pharmaceuticals Stock (NASDAQ:INM)

Key Stats

Today's Range
$4.97
$8.27
50-Day Range
$4.05
$5.50
52-Week Range
$2.41
$15.70
Volume
26.05 million shs
Average Volume
2.20 million shs
Market Capitalization
$3.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

InMed Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
24th Percentile Overall Score

INM MarketRank™: 

InMed Pharmaceuticals scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for InMed Pharmaceuticals.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of InMed Pharmaceuticals is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of InMed Pharmaceuticals is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    InMed Pharmaceuticals has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about InMed Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    1.29% of the outstanding shares of InMed Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    InMed Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in InMed Pharmaceuticals has recently decreased by 30.08%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    InMed Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    InMed Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.29% of the outstanding shares of InMed Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    InMed Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in InMed Pharmaceuticals has recently decreased by 30.08%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    InMed Pharmaceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for InMed Pharmaceuticals this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, InMed Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.85% of the stock of InMed Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 20.12% of the stock of InMed Pharmaceuticals is held by institutions.

  • Read more about InMed Pharmaceuticals' insider trading history.
Receive INM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INM Stock News Headlines

InMed’s Study Highlights Cannabinol’s Potential in Skincare
24/7 Automated Profits in Crypto
What if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast world of passive crypto income, where you set up a dependable income stream that works for you, whether you're at your computer or living your life.
InMed Pharmaceuticals Makes Progress on Alzheimer’s Drug
See More Headlines

INM Stock Analysis - Frequently Asked Questions

InMed Pharmaceuticals' stock was trading at $4.74 on January 1st, 2025. Since then, INM shares have increased by 7.9% and is now trading at $5.1150.
View the best growth stocks for 2025 here
.

InMed Pharmaceuticals Inc. (NASDAQ:INM) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($125.00) EPS for the quarter, topping analysts' consensus estimates of ($175.00) by $50.00. InMed Pharmaceuticals had a negative net margin of 137.41% and a negative trailing twelve-month return on equity of 65.74%.

InMed Pharmaceuticals shares reverse split on Wednesday, September 7th 2022. The 1-25 reverse split was announced on Wednesday, September 7th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of INM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that InMed Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), Tesla (TSLA) and PayPal (PYPL).

Company Calendar

Last Earnings
11/10/2021
Today
1/21/2025
Next Earnings (Estimated)
2/11/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:INM
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Net Income
$-7,680,000.00
Net Margins
-137.41%
Pretax Margin
-137.25%

Debt

Sales & Book Value

Annual Sales
$4.60 million
Book Value
$20.64 per share

Miscellaneous

Free Float
711,000
Market Cap
$3.67 million
Optionable
Not Optionable
Beta
0.23
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:INM) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners